Navigation Links
Techne Corporation Appoints Dr. J. Fernando Bazan As Chief Technology Officer
Date:7/23/2013

MINNEAPOLIS, July 23, 2013 /PRNewswire/ -- Techne Corporation (NASDAQ: TECH) (Techne) announced today that J. Fernando Bazan, Ph.D. has been appointed Chief Technology Officer. With global recognition as a scientific leader in fields ranging from structural biology to drug discovery for the treatment of human disorders, Dr. Bazan will be instrumental in directing innovation and influencing future growth in Techne's world-wide market.

Dr. Bazan joins Techne with more than twenty years of experience in academia and the biotechnology industry. Following training at Stanford University, the University of California Berkeley, and the University of California San Francisco, he served as a senior scientist at the DNAX Research Institute (Schering-Plough/Merck) and at Genentech (Roche) as well as serving as Chief Scientific Officer at NeuroScience, a neuroimmunology startup. Dr. Bazan holds an adjunct faculty appointment at the University of Minnesota School of Medicine where he applies pharmacological approaches to cancer and immune disorders and utilizes structural and computational insights to investigate signaling mechanisms in biological systems.

As a world renowned scientist, Dr. Bazan has shed light on important biological questions and set the groundwork for advances in the cell signaling and immunology fields. His technical expertise, interdisciplinary approach, and creativity led to the first classification system of the structural architectures of cytokines and their receptors. Dr. Bazan's research also produced numerous scientific breakthroughs including the identification of novel cytokines, their receptor complexes, and immune subsets (Th17 cells) that responded to these factors. This ability to drive global technical collaborations will help frame the strategic and platform decisions for the Company.

"We are delighted to welcome Dr. Bazan to the executive team at Techne," said Charles R. Kummeth, President and Chief Executive Officer of Techne. "His seminal discoveries of key cytokines are central to our business, and Dr. Bazan brings with him the technical expertise and vision to help lead the future of innovation at Techne."

Techne Corporation and Subsidiaries (the Company) are engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted through the Company's two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of biological products. R&D Systems has three subsidiaries: BiosPacific, Inc. (BiosPacific), located in Emeryville, California, Boston Biochem, Inc., located in Cambridge, Massachusetts, and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China. BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. Boston Biochem is a leading developer and manufacturer of ubiquitin-related research products. R&D China and R&D Europe distribute biotechnology products. R&D Europe has two subsidiaries: Tocris Holdings Ltd. (Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation. Tocris is a leading supplier of chemical reagents for non-clinical life science research.


'/>"/>
SOURCE Techne Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Medbox, Inc. Announces Top-Tier Rating by Dun & Bradstreet Credibility Corporation
2. ShanghaiBio Corporation Partners with Ingenuity Systems to Address Challenges in Analysis and Interpretation of Genomics Data
3. Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent
4. Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner
5. Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research
6. Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office
7. Verenium Corporation To Announce Fourth Quarter And Year End 2012 Financial Results
8. Hyland Software Partners with Communication Intelligence Corporation (CIC), a Leading Supplier of Electronic Signature Solutions
9. Homeland Security Corporation (HSCC) Appoints New President with Biometrics and Access Control Solutions Expertise and Contacts
10. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
11. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: